Compare · ABSI vs SLGC
ABSI vs SLGC
Side-by-side comparison of Absci Corporation (ABSI) and SomaLogic Inc. (SLGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and SLGC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI is the larger of the two at $1.59B, about 1.1x SLGC ($1.43B).
- ABSI has hit the wire 9 times in the past 4 weeks while SLGC has been quiet.
- ABSI has more recent analyst coverage (21 ratings vs 6 for SLGC).
- Company
- Absci Corporation
- SomaLogic Inc.
- Price
- $10.24+0.10%
- $2.09-5.43%
- Market cap
- $1.59B
- $1.43B
- 1M return
- +57.54%
- -
- 1Y return
- +299.22%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 21
- 6
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Chief Executive Officer Mcclain Sean covered exercise/tax liability with 59,896 shares, decreasing direct ownership by 0.69% to 8,655,555 units (SEC Form 4) (for tax liability)
- SEC Form 8-K filed by Absci Corporation
- SEC Form 424B5 filed by Absci Corporation
- Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
- Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits
- Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
- The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Latest SLGC
- OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form 15-12G filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Ryan Jason
- Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Post Richard A returned 57,430 shares to the company, closing all direct ownership in the company (SEC Form 4)